[{"Assets_0_Q2_USD":10074289000.0,"CommonStockSharesOutstanding_0_Q2_shares":226391081.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":86602000.0,"NetIncomeLoss_1_Q2_USD":-106005000.0,"NetIncomeLoss_2_Q2_USD":-124578000.0,"StockholdersEquity_0_Q2_USD":-590472000.0,"EarningsPerShareBasic_1_Q2_USD":-0.47,"EarningsPerShareBasic_2_Q2_USD":-0.55,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":226221000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":225408000.0,"Ticker":"ENDP","CIK":"1593034","name":"ENDO INTERNATIONAL PLC","OfficialName":"Endo International plc Ordinary Shares","form":"10-Q","period":"20190630","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"640358301.0","Country":"Ireland","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190805"}]